Allulose Market Access and Labeling Notes for U.S., EU and Australia-New Zealand Buyers
Direct answer: Allulose is attractive in sugar-reduction projects because it can help with sweetness, body and calorie positioning in markets where it is permitted. The difficult part is that market access and label treatment are not the same everywhere.
Published by Guilin Hengliyuan Biotech
This guide is for beverage, bakery, frozen dessert, confectionery, tabletop and private-label buyers who need a practical first check before asking for allulose, monk fruit, stevia or broader natural sweetener blend samples.
Start with the target market
Before choosing an allulose-based blend, confirm the country or region where the product will be sold, the final food category, the label language, the importer or distributor's compliance process and whether the buyer needs supplier documents for review.
United States: label treatment is specific
FDA guidance allows a different label approach for allulose than traditional sugars: allulose may be excluded from Total Sugars and Added Sugars and may use 0.4 calories per gram, while still being included in Total Carbohydrate. Buyers should still check formula, serving size, ingredient statement and claim wording before launch.
European Union: do not assume approval
For EU projects, buyers should treat allulose cautiously. EFSA's 2025 D-allulose novel food opinion concluded that safety could not be established from the submitted data, and EU novel foods need authorisation before they are placed on the market. A supplier discussion should not replace local regulatory review.
Australia and New Zealand: A1247 changed the path
FSANZ published Application A1247 for D-allulose as a novel food in August 2024, and Amendment No. 233 was gazetted in October 2024. Buyers still need to confirm food category, use level, ingredient source, label treatment and whether the final product fits the Food Standards Code.
Market access affects blend design
If allulose is suitable for the target market, it can be considered for body, sweetness rounding and sugar-reduction texture. If it is not suitable, a buyer may need a different system built around monk fruit, stevia, fiber, erythritol-free carriers or another permitted bulk direction.
What suppliers can prepare
Ask for specification, COA, production and food safety files, sample size, ingredient identity, intended application and any target-market support documents. Keep legal label approval with the buyer's local regulatory team or importer.
Official references
Reviewed July 2026. Source direction: FDA guidance on allulose declaration and calories; FDA page on sugars metabolized differently from traditional sugars; EFSA Journal 2025 D-allulose novel food opinion and EFSA novel food authorisation process; FSANZ Application A1247 and Amendment No. 233.
Related Hengliyuan products
Frequently asked questions
- Can the same allulose blend be sold in every market?
- No. Allulose status and label treatment differ by market, so buyers should confirm the target country, food category and local label rules before launch.
- Is allulose treated like sugar on U.S. labels?
- FDA guidance gives allulose a specific label treatment for Total Sugars, Added Sugars and calories, but it still needs to be handled correctly in the full Nutrition Facts and ingredient statement context.
- Can EU buyers request allulose samples?
- Samples can be discussed for technical evaluation, but EU commercial use needs local regulatory review because allulose should not be assumed authorised for sale.
- What should buyers send before asking for allulose blend samples?
- Start with your target market and product idea. Share any known packaging specification, estimated quantity, required certificates/documents and whether samples are needed; we can clarify the remaining details together.
What should buyers verify before a commercial discussion?
This is a buyer education Resource. It explains a natural sweetener, application, sourcing or validation question before a commercial discussion.
Product fit, label treatment, regulatory status and finished-product performance still need target-market and real-base checks.